Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06859658

Development and Validation of a Functional MRI Biomarker of Cerebral Small Vessel Dysfunction in CADASIL

Développement et Validation d'un Biomarqueur en IRM Fonctionnelle de la Dysfonction Des Petits Vaisseaux cérébraux Dans la Maladie de CADASIL

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
70 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Cerebral small vessel diseases (cSVD) are diseases of brain tissue involving vessels (arterioles or capillaries) with a diameter of less than 400 microns. Within this group, CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is the most common familial form. CADASIL is due to mutations in the NOTCH3 gene located on chromosome 19. It is considered a unique model for the study of cSVD. CADASIL begins between the ages of 20 and 40, with the appearance of cerebral white matter hyper-signals visible on MRI. Before the age of 30, patients are usually asymptomatic. To date, there are no available treatments. To test new therapeutic approaches, we need biomarkers that are robust and sensitive enough to assess the effects of these treatments at an early stage of cSVD and over a relatively short period of time. An ideal monitoring biomarker should be repeatedly and safely usable, easily accessible, accurate, reproducible and sensitive to disease progression or pharmacological intervention. Alterations in neurovascular coupling (NVC) have been recognized as one of the earliest functional alterations occurring during cSVD. Cerebral functional magnetic resonance imaging (fMRI) is a brain imaging technique that measures the activity of brain areas in vivo by detecting local changes in blood flow. An important advantage of blood oxygen level-dependent functional MRI is that it enables the NVC to be probed in vivo, safely and repeatedly in humans. Our central hypothesis is that functional MRI can provide such a biomarker for monitoring CNV disease progression in vivo using a dedicated fMRI protocol that can be used on a clinical MRI scanner, is reproducible and varies according to the severity of brain MRI lesions and/or clinical manifestations in CADASIL. A functional imaging study coupled with electroencephalogram has already revealed changes in the hemodynamic response to visual or motor stimuli in patients at the early stage of the disease. This study is exploring new imaging protocols to focus on the purest vascular response.

Conditions

Interventions

TypeNameDescription
RADIATIONFunctional MRI at 3TAt inclusion
RADIATIONFunctional MRI at 3TAt inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)
RADIATIONFunctional MRI at 3TAt inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)

Timeline

Start date
2025-04-01
Primary completion
2029-04-01
Completion
2029-04-01
First posted
2025-03-05
Last updated
2025-03-05

Source: ClinicalTrials.gov record NCT06859658. Inclusion in this directory is not an endorsement.